Do not push the plunger in
FDA approval as a new oral treatment for idiopathic pulmonary fibrosis (IPF) in adults marking a major milestone in respiratory medicine
I outline a way to play the picks and shovels of this issue, but it is also indicative of the fact that there is significant demand and further impact to be had for this theme - simply put, not enough people are on it yet
Employers can choose to make the program broadcovering a wide array of lifestyle and wellbeing categoriesor focus on specific areas such as professional development, family support, or financial wellness benefits
This guide compares the two on mechanism, efficacy, approval status, cost, and side effects, then explains which one fits which situation